Eli Lilly Retatrutide Achieves Phase 3 Obesity Weight Loss Eli Lilly's retatrutide met primary endpoint. Phase 3 trial showed significant weight loss. Patients lost approximately 25% body weight. This sets a new efficacy benchmark. Eli Lilly announced groundbreaking Phase 3 results for retatrutide in obesity. The "triple-G" agonist demonstrated an average weight reduction of roughly 25%. This efficacy was the primary endpoint, measured as percentage change from baseline body weight. The trial's success positions retatrutide as a potential best-in-class therapy, advancing obesity treatment options. These robust Phase 3 results pave the way for regulatory submissions. Eli Lilly will likely pursue accelerated approval pathways with the FDA and EMA. The data supports a strong efficacy profile, crucial for marketing authorization under 21 CFR Part 314 (FDA) and EMA centralized procedures. Expect New Drug Application (NDA) and Marketing Authorization Application (MAA) filings in late 2026 or early 2027. Retatrutide's performance intensifies competition in the obesity market. It challenges existing therapies like Novo Nordisk's Wegovy and Eli Lilly's own Zepbound. This high efficacy could capture substantial market share. Competitors will face pressure to innovate. Expect market impact by Q3 2027, pending regulatory approvals.